COVID-19 Clinical Trial
Official title:
Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System
In the current COVID-19 pandemic with coronavirus, SARS-COV2, the Danish Health Authorities
recommend using facial masks in the health care system when handling patients presumed or
proven to be infected with the virus. However, the use of facial masks outside the health
care system is not recommended by the Danish Health Authorities. Here, Health Authorities in
other countries have different recommendations for the use of facial masks.
Challenges when using facial masks outside the health care system include wearing the mask
consistently, an efficacy of the mask of app. 8 hours necessitating a change of mask
throughout the day, and that it is not sufficiently tight enough to safely keep the virus
out. Moreover, the eyes (mucous membrane) remain exposed. Compliance could also be another
challenge.
SARS-COV2 is assumed to primarily enter the body via the mouth through respiratory droplets -
or possibly through inhalation of aerosol containing the virus. From the mouth the virus is
assumed to spread to the airways and the gastro-intestinal tract. SARS-COV2 is also known to
be transmitted via physical contact, helped along by the fact that the virus can survive on
surfaces for at least 72 hours. Touching such a contaminated surface can transfer the virus
to the mouth via the hand - and thus lead to infection of the person.
Facial masks are expected to protect against viral infection in two ways;
1. By reducing the risk of getting the virus in via the mouth or nose via respiratory
droplets or aerosol
2. By reducing the transfer from virus-contaminated hands to the mouth or nose
Hypothesis The use of surgical facial masks outside the hospital will reduce the frequency of
COVID-19 infection.
All participants will follow authority recommendations and be randomized to either wear
facial masks or not. The participants will be screened for antibodies at study start and
study end. They will perform swab-test if they experience symptoms during the study as well
as the end of study.
Background In the current COVID-19 pandemic with coronavirus, SARS-COV2, the Danish Health
Authorities recommend using facial masks in the health care sector when handling patients
presumed or proven to be infected with the virus. However, the use of facial masks outside
the healthcare system is not recommended by the Danish Health Authorities. Challenges when
using facial masks outside the health care system include wearing the mask consistently, an
efficacy of the mask of app. 8 hours necessitating a change of mask throughout the day, and
that it is not sufficiently tight enough to safely keep the virus out. Moreover, the eyes
(mucous membrane) remain exposed. Compliance could also be another challenge. Health
Authorities in other countries have different recommendations for the use of facial masks and
the authors of the Lancet study concluded; "Universal use of face masks could be considered
if supplies permit. In parallel, urgent research on the duration of protection of face masks,
the measures to prolong life of disposable masks, and the invention on reusable masks should
be encouraged."
SARS-COV2 is assumed to primarily enter the body via the mouth through respiratory droplets
or possibly through inhalation of aerosol containing the virus. From the mouth the virus is
assumed to spread to the airways and the gastro-intestinal tract. SARS-COV2 is also known to
be transmitted via physical contact, helped along by the fact that the virus can survive on
surfaces for at least 72 hours. Touching such a contaminated surface can transfer the virus
to the mouth via the hand - and thus lead to infection of the person. A study with 26 medical
students showed that they touched their face on average 23 times per hour, and that in 44 %
of the incidents they touched their mucous membranes3. A Japanese questionnaire study showed
that facial masks reduced the risk for school children for getting influenza by 15 %4. N95
mask and surgical facial masks are presumed to have the same effect for healthcare personnel
when providing protecting from infection with influenza.
Facial masks are assumed to protect against viral infection in two ways;
1. By reducing the risk of getting the virus via mouth or nose through the air via
respiratory droplets or aerosol
2. By reducing the transfer from virus-contaminated hands to the mouth or nose
About 10 % of the Danish population is estimated to get COVID-19 during the present
pandemic-wave; this corresponds to 600,000 Danes. Later COVID-19 waves are expected to occur.
The epidemic in Denmark is expected to be at the highest point in medio April. In April and
May it be estimated that >2 % of the population will be infected per month.
Hypothesis The use of surgical facial masks outside the hospital will reduce the frequency of
COVID-19 infection.
Method The participants recruited are people working outside of their home, who have not
previously been infected with COVID-19 and who do not wear facial masks (e.g. healthcare
personnel) when working. They will be randomized for
1. Normal behavior according to the authority's recommendations or
2. Normal behavior according to the authority's recommendations and use of facial masks
Participants will be instructed in using the facial mask consistently when outside their home
(and at home when receiving visits from others. The instruction is given in writing and via
an instruction video. The participants will be contacted once weekly to optimize compliance.
It will be registered if the participants are diagnosed with COVID-19. Participants, who are
not tested positive for COVID-19 in the study period will perform a self-test if having
symptoms or when the study ends (instruction video).
Perspective The study can determine whether use of facial masks in the public is beneficial
and if there is an effect this could have great impact on the current as well as any future,
similar epidemics.
Interested participants can register through a link in the add to our research registration
database RedCap. The participant will then receive written information and can then register.
They will receive a COVID-19 screening test set and (+/-) facial masks ( 2 per day) for the
first month. If the participant experience symptoms, he/she will register their symptoms in
RedCap, test with a swab-test and send the swab-test to the study investigator for analyses.
If negative, new test-sets are sent out - if positive, the participant will be referred to
the hospital. This process continues until the participant is tested positive for COVID-19,
the pandemic is considered finished by the Danish authorities or when the study ends on May 7
2020. At study end, all participants perform antibody screening and swab test, and send it to
the study investigators.
Power calculation With an infection frequency of 2 % in the study period, an expected
reduction of the risk to 1 % should be demonstratable with a power of 80 % and a p-value of 5
%, if including a total of 4,636 patients randomized 1:1. If the infection frequency is
higher the power of the study will be higher. With an expected defection of 20 % a total of
6,000 participants will be included.
Authority approvals from The Danish National Committee On Health Research Ethics and The Data
Protection Agency have been granted.
A detailed study analyses plan (SAP) will be finalized before data are analyzed.
Central registry data will be collected later when made available by national health
authorities.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|